Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $155,200.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the sale, the director directly owned 6,068,287 shares of the company’s stock, valued at approximately $23,544,953.56. This represents a 0.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $3.52 on Friday. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $5.24. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -3.91 and a beta of 1.15. The business has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $3.52. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 46.47%. The business had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. During the same quarter last year, the firm earned ($0.36) EPS. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RXRX shares. Morgan Stanley set a $5.90 target price on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.18.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $7,370,000. Hsbc Holdings PLC raised its position in shares of Recursion Pharmaceuticals by 537.3% in the 4th quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock worth $3,367,000 after buying an additional 689,903 shares during the period. Bank of America Corp DE raised its holdings in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after purchasing an additional 384,486 shares during the period. First Trust Advisors LP raised its holdings in shares of Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after purchasing an additional 344,035 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Recursion Pharmaceuticals by 29.3% during the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.